Alfacalcidol Supplementation on Levator Ani Muscle Strength of Menopausal Pelvic Organ Prolapse Patients
1 other identifier
interventional
48
1 country
1
Brief Summary
This is a study performed to evaluate the role of vitamin D supplementation on the strength of levator ani muscle in menopausal women with pelvic organ prolapse
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_3
Started Nov 2020
Shorter than P25 for phase_3
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2021
CompletedFirst Submitted
Initial submission to the registry
August 15, 2022
CompletedFirst Posted
Study publicly available on registry
August 17, 2022
CompletedAugust 17, 2022
August 1, 2022
12 months
August 15, 2022
August 15, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Vitamin D3 levels
Vitamin D3 levels measured using lab tests
3 months
Vitamin D receptor levels
Vitamin D receptor levels as assessed by ELISA
3 months
Levator ani muscle strength
Levator ani muscle strength as measured using anometry
3 months
Study Arms (2)
Alfacalcidol
ACTIVE COMPARATORAlfacalcidol 0.5 mcg orally given for 3 months
Control
PLACEBO COMPARATORPlacebo given orally for 3 months
Interventions
Alfacalcidol 0.5 mcg is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
Placebo drug is given orally for 3 months, then vitamin D3 and vitamin D receptor levels are measured
Eligibility Criteria
You may qualify if:
- patients with pelvic organ prolapse stages III and IV who underwent surgery at menopausal age
- normal BMI
- initial serum vitamin D levels \<30 ng/mL
You may not qualify if:
- comorbidities (chronic cough, conspitation)
- vitamin D metabolism or immune system interfering diseases or drugs specific routine medications such as anticonvulsants, statin, fibrate or orlistat
- history of vitamin D supplementation within the last month
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Universitas Padjadjaran
Bandung, West Java, 40161, Indonesia
Related Publications (2)
Zhang L, Quan M, Cao ZB. Effect of vitamin D supplementation on upper and lower limb muscle strength and muscle power in athletes: A meta-analysis. PLoS One. 2019 Apr 30;14(4):e0215826. doi: 10.1371/journal.pone.0215826. eCollection 2019.
PMID: 31039170RESULTLatham CM, Brightwell CR, Keeble AR, Munson BD, Thomas NT, Zagzoog AM, Fry CS, Fry JL. Vitamin D Promotes Skeletal Muscle Regeneration and Mitochondrial Health. Front Physiol. 2021 Apr 14;12:660498. doi: 10.3389/fphys.2021.660498. eCollection 2021.
PMID: 33935807RESULT
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
RM Sonny Sasotya, Ph.D.
Universitas Padjadjaran
Study Design
- Study Type
- interventional
- Phase
- phase 3
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 15, 2022
First Posted
August 17, 2022
Study Start
November 1, 2020
Primary Completion
October 31, 2021
Study Completion
December 31, 2021
Last Updated
August 17, 2022
Record last verified: 2022-08
Data Sharing
- IPD Sharing
- Will share
- Shared Documents
- STUDY PROTOCOL, SAP, ICF, CSR
- Time Frame
- until 31 December 2026
- Access Criteria
- Access will be given upon written request to the authorrs
Anonymised patient data are available upon written request to the authors